ACM
JBIO

Aster Capital Management’s Jade Biosciences JBIO Stock Holding History

Aster Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Buy
+1,176
New +$24.5K 0.01% 583
2026
Q1 		– Sell
-95
Closed -$1.47K – 865
2025
Q4 		$1.47K Buy
+95
New +$1.11K ﹤0.01% 986

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aster Capital Management's JBIO Position: Q2 2026 in Review

Aster Capital Management opened a new position in Jade Biosciences (JBIO) in Q2 2026: 1,176 shares worth $26.1K. The stake represents 0.01% of the portfolio and ranks #583 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in JBIO as recently as Q4 2025.

Aster Capital Management first reported a position in JBIO in Q4 2025 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Aster Capital Management held 1,176 shares of Jade Biosciences worth $26.1K as of Q2 2026.
  • Jade Biosciences was a new Aster Capital Management position in Q2 2026.
  • Jade Biosciences made up 0.01% of Aster Capital Management's portfolio in Q2 2026, its #583 holding.
  • Aster Capital Management first reported a position in Jade Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.